How Cancer Cells Silence PHD3 Expression
Author Information
Author(s): Trenton L. Place, Matthew P. Fitzgerald, Sujatha Venkataraman, Sabine U. Vorrink, Adam J. Case, Melissa L. T. Teoh, Frederick E. Domann
Primary Institution: The University of Iowa
Hypothesis
The study investigates whether aberrant methylation of the PHD3 promoter is responsible for its silencing in various cancer cell lines.
Conclusion
PHD3 expression is silenced by aberrant CpG methylation in several human carcinoma cell lines, which prevents its upregulation under hypoxic conditions.
Supporting Evidence
- PHD3 mRNA expression was nearly undetectable in certain cancer cell lines.
- Treatment with a demethylating agent significantly increased PHD3 expression.
- Hypermethylation of the PHD3 promoter was observed in multiple cancer cell lines.
Takeaway
Some cancer cells don't make a protein called PHD3 because a part of their DNA that tells them to make it is turned off. This can happen because of a process called methylation.
Methodology
The study used bisulfite sequencing and methylated DNA enrichment procedures to analyze PHD3 promoter methylation in various cancer cell lines.
Limitations
The study did not find PHD3 promoter methylation in primary human prostate tumors, suggesting that the findings may not apply to all cancer types.
Participant Demographics
The study analyzed various human carcinoma cell lines, including prostate, breast, melanoma, and renal cancer cells.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website